Johnson & Johnson subsidiary Cilag GmbH International will pay a total of $330 million to AstraZeneca for rights to Rhinocort Aqua budesonide nasal spray outside of the US, AstraZeneca has announced. Cilag operates as part of J&J’s Janssen Pharmaceutical Companies.
A US J&J subsidiary, McNeil Consumer Healthcare, acquired US OTC rights to Rhinocort Aqua in 2014 and launched the OTC version of Rhinocort Aqua in February 2016.
According to AstraZeneca, the deal will not affect any employees or facilities.
AstraZeneca Executive VP, Global Product & Portfolio Strategy, commented, “This agreement allows us to concentrate our efforts in Respiratory as one of our three strategic therapy areas, on transforming the treatment of asthma and COPD, where budesonide remains a key component of our marketed as well as pipeline medicines.”
Read the AstraZeneca press release.
